The cash flow statement provides information about a company cash receipts and cash payments during an accounting period, showing how these cash flows link the ending cash balance to the beginning balance shown on the company balance sheet.
The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.
Eli Lilly & Co., consolidated cash flow statement (quarterly data)
US$ in thousands
3 months ended:
Sep 30, 2024
Jun 30, 2024
Mar 31, 2024
Dec 31, 2023
Sep 30, 2023
Jun 30, 2023
Mar 31, 2023
Dec 31, 2022
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021
Sep 30, 2021
Jun 30, 2021
Mar 31, 2021
Dec 31, 2020
Sep 30, 2020
Jun 30, 2020
Mar 31, 2020
Dec 31, 2019
Sep 30, 2019
Jun 30, 2019
Mar 31, 2019
Net income (loss)
970,300)
2,967,000)
2,242,900)
2,189,700)
(57,400)
1,763,200)
1,344,900)
1,937,700)
1,451,700)
952,500)
1,902,900)
1,726,100)
1,110,100)
1,390,200)
1,355,300)
2,116,800)
1,208,400)
1,412,000)
1,456,500)
1,495,700)
1,253,900)
1,327,200)
4,241,600)
Gain related to disposition of Elanco
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
(3,680,500)
Gain on sale of antibiotic business in China
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
(309,800)
—)
—)
—)
Depreciation and amortization
466,800)
414,400)
400,600)
387,700)
411,000)
366,300)
362,300)
375,000)
362,900)
348,900)
435,700)
445,700)
382,300)
369,300)
350,300)
367,500)
358,400)
324,400)
273,600)
340,700)
288,000)
247,400)
356,500)
Change in deferred income taxes
(429,800)
(1,007,600)
(279,000)
(506,200)
(844,300)
(431,100)
(559,400)
10,400)
(1,070,600)
(618,400)
(506,600)
(92,500)
(296,000)
(294,700)
(119,100)
(200,700)
159,700)
(104,700)
11,200)
85,800)
(12,100)
61,100)
(72,400)
Debt extinguishment loss
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
405,200)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
Stock-based compensation expense
133,200)
211,100)
159,400)
120,200)
215,600)
161,500)
131,200)
92,900)
85,100)
92,100)
101,000)
75,300)
90,100)
91,900)
85,500)
87,800)
71,700)
76,800)
71,800)
81,600)
75,500)
79,500)
75,800)
Net investment (gains) losses
(112,400)
158,000)
(15,800)
(121,000)
64,500)
65,800)
14,200)
(256,400)
130,800)
119,500)
426,100)
93,100)
247,000)
(215,900)
(302,200)
(529,000)
(144,500)
(578,300)
(186,700)
(225,500)
(50,100)
(127,500)
—)
Gains on sale of product rights
(100,700)
—)
—)
(25,000)
(1,853,900)
—)
—)
(62,000)
(94,500)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
Acquired in-process research and development
2,826,400)
154,300)
110,500)
622,600)
2,975,100)
97,100)
105,000)
168,900)
19,000)
80,000)
153,000)
376,600)
174,000)
25,000)
299,300)
366,300)
—)
241,800)
52,300)
—)
77,700)
25,000)
136,900)
Other changes in operating assets and liabilities, net of acquisitions and divestitures
(9,800)
(1,399,100)
(1,751,200)
(3,172,200)
793,300)
(840,200)
164,100)
(836,000)
939,100)
(72,100)
(45,500)
(474,500)
(666,500)
221,200)
(102,800)
(515,200)
249,400)
926,500)
(1,408,100)
76,500)
(247,300)
(802,100)
(714,300)
Other operating activities, net
(32,100)
(31,900)
298,600)
192,300)
485,600)
(550,700)
168,300)
149,200)
361,300)
(81,800)
32,600)
6,700)
185,100)
188,500)
131,100)
121,700)
(96,500)
196,900)
111,800)
418,700)
124,500)
240,900)
(32,300)
Adjustments to reconcile net income (loss) to cash flows from operating activities
2,741,600)
(1,500,800)
(1,076,900)
(2,501,600)
2,246,900)
(1,131,300)
385,700)
(358,000)
733,100)
(131,800)
596,300)
430,400)
521,200)
385,300)
342,100)
(301,600)
598,200)
1,083,400)
(1,074,100)
468,000)
256,200)
(275,700)
(3,930,300)
Net cash provided by operating activities
3,711,900)
1,466,200)
1,166,000)
(311,900)
2,189,500)
631,900)
1,730,600)
1,579,700)
2,184,800)
820,700)
2,499,200)
2,156,500)
1,631,300)
1,775,500)
1,697,400)
1,815,200)
1,806,600)
2,495,400)
382,400)
1,963,700)
1,510,100)
1,051,500)
311,300)
Purchases of property and equipment
(1,350,700)
(1,224,800)
(986,300)
(1,070,600)
(970,300)
(738,200)
(668,500)
(500,700)
(617,200)
(371,000)
(365,400)
(291,400)
(336,800)
(381,300)
(300,300)
(454,700)
(393,100)
(281,800)
(258,300)
(326,500)
(263,400)
(240,300)
(203,700)
Proceeds from sales and maturities of short-term investments
31,900)
34,000)
41,400)
37,000)
45,600)
48,100)
61,500)
38,300)
25,500)
30,900)
26,700)
800)
25,300)
17,300)
4,000)
10,900)
7,600)
74,400)
36,800)
20,300)
26,900)
53,500)
35,900)
Purchases of short-term investments
(19,800)
(24,400)
(24,400)
(19,000)
(19,400)
(36,800)
(23,000)
(42,400)
(32,100)
(18,300)
(14,600)
(55,600)
(1,300)
(7,200)
(19,400)
—)
(11,400)
—)
—)
(8,600)
—)
(400)
(33,700)
Proceeds from sales of and distributions from noncurrent investments
67,900)
179,600)
70,500)
31,900)
87,800)
106,500)
281,900)
90,600)
83,100)
87,100)
81,400)
262,800)
75,300)
177,100)
284,800)
183,000)
162,100)
357,500)
54,500)
111,400)
82,000)
332,800)
83,600)
Purchases of noncurrent investments
(275,000)
(133,000)
(117,100)
(256,000)
(131,400)
(197,400)
(146,000)
(126,100)
(222,700)
(134,700)
(116,700)
(219,800)
(207,000)
(211,600)
(291,500)
(135,000)
(68,900)
(71,800)
(83,000)
(50,800)
(50,100)
(86,000)
(60,600)
Proceeds from sale of product rights
530,900)
—)
—)
—)
1,604,300)
—)
—)
30,000)
65,800)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
Cash paid for acquisitions, net of cash acquired
—)
(947,700)
—)
(1,044,300)
—)
—)
—)
(327,200)
—)
—)
—)
—)
—)
—)
(747,400)
—)
—)
—)
(849,300)
—)
—)
—)
(6,917,700)
Purchases of in-process research and development
(2,820,100)
(178,000)
(96,500)
(580,500)
(3,030,900)
(98,100)
(235,000)
(54,900)
(3,000)
(80,000)
(491,800)
(102,800)
(118,800)
(150,000)
(191,800)
(364,800)
(22,000)
(241,400)
(13,000)
—)
(77,700)
(45,000)
(196,900)
Cash distributed to Elanco upon disposition
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
(374,000)
—)
—)
—)
Cash received for sale of antibiotic business in China
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
—)
354,800)
—)
—)
—)
Other investing activities, net
(169,800)
95,600)
(65,200)
(22,800)
(666,200)
456,800)
40,300)
31,900)
(222,800)
22,100)
(133,400)
27,000)
(53,200)
72,400)
(21,900)
86,500)
12,200)
(47,300)
51,400)
232,000)
(141,500)
46,400)
(385,600)
Net cash used for investing activities
(4,004,700)
(2,198,700)
(1,177,600)
(2,924,300)
(3,080,500)
(459,100)
(688,800)
(860,500)
(923,400)
(463,900)
(1,013,800)
(379,000)
(616,500)
(483,300)
(1,283,500)
(674,100)
(313,500)
(210,400)
(1,060,900)
(41,400)
(423,800)
61,000)
(7,678,700)
Dividends paid
(1,170,500)
(1,172,400)
(1,169,200)
(1,018,100)
(1,016,200)
(1,017,800)
(1,017,200)
(884,400)
(882,200)
(883,700)
(885,500)
(773,300)
(770,400)
(768,300)
(774,800)
(670,000)
(671,600)
(674,200)
(671,300)
(587,200)
(587,400)
(598,000)
(637,200)
Net change in short-term borrowings
(3,089,400)
3,400,100)
(5,204,800)
4,594,400)
1,595,000)
—)
(1,498,000)
(243,300)
(375,900)
1,617,500)
499,700)
(2,500)
(197,800)
200,000)
(3,700)
(579,900)
(678,900)
(1,984,100)
1,748,700)
(63,500)
(505,400)
(286,100)
1,850,400)
Proceeds from issuance of long-term debt
4,964,600)
—)
6,452,500)
—)
—)
—)
3,958,500)
—)
—)
—)
—)
—)
2,410,800)
—)
—)
—)
1,073,700)
988,600)
—)
2,108,100)
—)
—)
4,448,300)
Repayments of long-term debt
—)
(664,200)
—)
—)
—)
—)
—)
—)
—)
(849,900)
(710,100)
(100)
(1,905,300)
—)
—)
(200)
—)
—)
(276,300)
(2,266,100)
(100)
(200)
(600,000)
Purchases of common stock
(446,100)
—)
—)
—)
—)
—)
(750,000)
—)
—)
—)
(1,500,000)
(750,000)
—)
(500,000)
—)
—)
—)
—)
(500,000)
(300,000)
(600,000)
—)
(3,500,000)
Other financing activities, net
(47,300)
(8,000)
(389,800)
(31,600)
(6,800)
(15,600)
(281,000)
(13,700)
(5,200)
(7,600)
(282,400)
(600)
(500)
(14,900)
(279,900)
(41,400)
(2,300)
(3,500)
(194,400)
(4,900)
—)
(1,500)
(193,700)
Net cash provided by (used for) financing activities
211,300)
1,555,500)
(311,300)
3,544,700)
572,000)
(1,033,400)
412,300)
(1,141,400)
(1,263,300)
(123,700)
(2,878,300)
(1,526,500)
(463,200)
(1,083,200)
(1,058,400)
(1,291,500)
(279,100)
(1,673,200)
106,700)
(1,113,600)
(1,692,900)
(885,800)
1,367,800)
Effect of exchange rate changes on cash and cash equivalents
226,900)
(59,600)
(35,500)
129,300)
5,300)
9,200)
24,800)
(128,200)
(3,600)
(69,400)
33,600)
(220,700)
16,600)
8,600)
(10,200)
212,200)
16,200)
54,300)
(66,700)
(35,000)
(119,800)
27,100)
37,800)
Net increase (decrease) in cash and cash equivalents
Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Eli Lilly & Co. net cash provided by operating activities increased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Net cash used for investing activities
Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Eli Lilly & Co. net cash used for investing activities decreased from Q1 2024 to Q2 2024 and from Q2 2024 to Q3 2024.
Net cash provided by (used for) financing activities
Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Eli Lilly & Co. net cash provided by (used for) financing activities increased from Q1 2024 to Q2 2024 but then slightly decreased from Q2 2024 to Q3 2024 not reaching Q1 2024 level.
